PDUFA Date

Elevar's lirafugratinib faces Sept. 27 FDA decision on 46.5% ORR in bile duct cancer

Priority review for the FGFR2 inhibitor rests on a single-arm response rate in FGFR2 fusion-positive cholangiocarcinoma, with no other FGFR2-targeted drug in Phase 3 for this population.

By AppliedXLJuly 13, 2026Trial NCT04526106

Executive Summary

The FDA has accepted Elevar's application for lirafugratinib in a narrow, previously treated bile duct cancer population and will decide by late September, with priority review signaling the agency already sees a case for accelerated action.
The application rests on a single-arm response rate from the drug's first-in-human study rather than a randomized trial, meaning durability and comparative benefit remain the open clinical questions even as objective response looks favorable.
Beyond the original priority review grant, the FDA has since added Fast Track and Orphan Drug designations, a sequence of positive signals that together describe an agency treating this application as addressing a serious unmet need.
No other FGFR2-targeted therapy has reached Phase 3 in this specific fusion-positive, previously treated cholangiocarcinoma population, leaving lirafugratinib to compete against the established standard rather than a head-to-head rival.

The filing and the date

The FDA completed its filing review of Elevar's New Drug Application for lirafugratinib and granted priority review, setting a Prescription Drug User Fee Act target action date of September 27, 2026, the company said. Priority review compresses the standard review timeline and is reserved for drugs the FDA believes could offer significant improvements in safety or effectiveness for a serious condition. The application covers cholangiocarcinoma, also known as bile duct cancer, in patients with FGFR2 fusions or rearrangements who have already received prior therapy, a population the American Cancer Society estimates at about 8,000 new U.S. diagnoses annually across all cholangiocarcinoma types. Elevar

The evidence package

Elevar's priority review rests on data from the Phase 1/2 REFOCUS trial, which enrolled 490 patients and reported a confirmed objective response rate of 46.5% in patients matching the proposed indication. The company said lirafugratinib's safety profile has been predictable and manageable through dose adjustments. REFOCUS ran as a first-in-human, dose-escalation and expansion study starting September 2020, primarily completing September 5, 2025, and is not designed as a randomized trial, so the ORR stands without a concurrent comparator arm. Elevar+1

Regulatory signal stacking

Since the March 2026 filing acceptance, the FDA has granted lirafugratinib both Fast Track and Orphan Drug designations, the company disclosed in a June 22, 2026 announcement. Fast Track allows more frequent FDA interaction and rolling review; Orphan Drug status confers market exclusivity for rare-disease treatments but does not by itself signal an approval outcome. Combined with the earlier priority review grant and a 2022 orphan drug designation tied to the same compound (then known as RLY-4008) for cholangiocarcinoma broadly, the FDA has now applied four separate positive procedural signals to this program ahead of its decision.

The competitive landscape

No other FGFR2-targeted therapy has advanced to Phase 3 in FGFR2 fusion-positive, previously treated cholangiocarcinoma specifically; the broader FGFR2-in-cholangiocarcinoma field includes 12 active industry trials, but Phase 1 outcomes for this exact target-indication pairing split evenly, with one completed and one terminated program on record. Pemigatinib, an approved FGFR2 inhibitor from Incyte, and infigratinib, from QED Therapeutics, both target FGFR-altered cholangiocarcinoma but are being studied or marketed in adjacent populations rather than head-to-head against lirafugratinib in this trial's eligible group. The nearest mechanism comparator identified for treatment of FGFR2-altered tumors more broadly is a VEGFR-targeted regorafenib study in hepatocellular carcinoma, a different target class entirely, underscoring that lirafugratinib's direct FGFR2 rivals in this specific fusion-positive setting remain limited.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.